Arcadia Investment Management Corp MI Acquires 6,326 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Arcadia Investment Management Corp MI raised its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 16.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 44,940 shares of the company’s stock after acquiring an additional 6,326 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in Dyne Therapeutics were worth $1,059,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DYN. Creative Planning raised its holdings in Dyne Therapeutics by 41.5% in the third quarter. Creative Planning now owns 10,605 shares of the company’s stock worth $381,000 after purchasing an additional 3,111 shares during the period. Values First Advisors Inc. acquired a new stake in Dyne Therapeutics in the third quarter worth $62,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Dyne Therapeutics by 67.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,310 shares of the company’s stock worth $694,000 after purchasing an additional 7,812 shares during the period. Finally, US Bancorp DE raised its holdings in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. 96.68% of the stock is owned by institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the transaction, the insider now directly owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 20.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on DYN shares. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Friday, January 10th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $49.91.

Dyne Therapeutics Trading Up 1.2 %

Shares of DYN stock opened at $13.99 on Friday. Dyne Therapeutics, Inc. has a 1 year low of $13.07 and a 1 year high of $47.45. The firm’s fifty day moving average price is $18.36 and its two-hundred day moving average price is $28.94.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.